colistin

简明释义

英[kəˈlɪstɪn]美[kəˈlɪstɪn]

n. [药] 粘菌素（用于治疗肠胃炎）

英英释义

单词用法

同义词

反义词

例句

1.A method was established to simultaneously detect colistin, bacitracin, virginiamycin residues in animal tissues, such as muscle, liver and kidney, by liquid chromatography tandem mass spectrometry.

建立了动物组织(肌肉、肝脏、肾脏)中粘杆菌素、杆菌肽和维吉尼霉素等多肽类抗生素残留量的检测方法。

2.Certain antibiotics such as colistin, streptomycin, kanamycin and so have the effect of increasing weakness, it should be noted.

某些抗生素、如粘菌素、链霉素、卡那霉素等均有加重肌无力之作用，应当注意。

3.A method was established to simultaneously detect colistin, bacitracin, virginiamycin residues in animal tissues, such as muscle, liver and kidney, by liquid chromatography tandem mass spectrometry.

建立了动物组织(肌肉、肝脏、肾脏)中粘杆菌素、杆菌肽和维吉尼霉素等多肽类抗生素残留量的检测方法。

4.NDM-1 was mostly found among Escherichia coli (36) and Klebsiella pneumoniae (111), which were highly resistant to all antibiotics except to tigecycline and colistin.

NDM-1基因多存在于大肠杆菌（36份）和肺炎克雷伯杆菌（111份）中，携该基因的细菌对除替加环素和黏菌素外的抗生素普遍耐药。

5.Food and Feed Additives: crumb, vanillin, protein-calcium power, starch, shrimp shell, xylitol, calcium pantothenate, colistin sulfate, tea power, D-calcium pantothenate, alanine;

食品和饲料添加剂：面包屑、香兰素、蛋白钙粉、淀粉、虾壳、木糖醇、泛酸钙、硫酸粘杆菌素、茶粉、D-泛酸钙、丙氨酸；

6.Zinc Bacitracin and penicillin, streptomycin, neomycin, chlortetracycline, colistin, which are synergistic antibacterial effect.

杆菌肽锌与青霉素、链霉素、新霉素、金霉素、黏菌素等有协同抗菌作用。

7.Despite being administered colistin, a powerful antibiotic, the patient died, the doctor said.

医生表示，已经给患者使用了药性极强的黏菌素抗生素，仍未能挽回他的生命。

8.Objective : To establish a microbiological test method for Colistin Sulfate Granules.

目的：建立硫酸粘菌素颗粒的微生物限度检验方法。

9.Researchers are studying the effectiveness of colistin against multidrug-resistant bacteria.

研究人员正在研究多粘菌素对多药耐药细菌的有效性。

10.Due to antibiotic resistance, colistin has become a last-resort treatment option.

由于抗生素耐药性，多粘菌素已成为最后的治疗选择。

11.The use of colistin in veterinary medicine has raised concerns about its impact on human health.

在兽医医学中使用多粘菌素引发了对其对人类健康影响的担忧。

12.Patients receiving colistin must be monitored closely for potential side effects.

接受多粘菌素治疗的患者必须密切监测潜在的副作用。

13.The doctor prescribed colistin to treat the patient's severe infection.

医生开了多粘菌素来治疗患者的严重感染。

作文

Colistin is a polymyxin antibiotic that has gained significant attention in recent years due to its effectiveness against multidrug-resistant bacteria. Originally discovered in the 1940s, colistin was largely forgotten as newer antibiotics were developed. However, with the rise of antibiotic resistance, especially among Gram-negative bacteria, colistin has made a comeback as a last-resort treatment option. This resurgence has sparked discussions about its use, effectiveness, and the potential consequences of relying on such an old drug in modern medicine.The mechanism of action of colistin involves disrupting the bacterial cell membrane, leading to cell death. This is particularly effective against bacteria like Escherichia coli and Klebsiella pneumoniae, which have become notorious for their resistance to multiple antibiotics. Despite its effectiveness, the use of colistin is not without risks. It can cause nephrotoxicity, which means it can damage the kidneys, especially when used in high doses or for extended periods.In clinical settings, colistin is often reserved for severe infections where other antibiotics have failed. Its use is typically guided by susceptibility testing, ensuring that it is only administered when absolutely necessary. This cautious approach is crucial because the indiscriminate use of colistin can lead to further resistance, making it less effective in the future.The reintroduction of colistin into treatment protocols raises ethical questions about antibiotic stewardship. Healthcare providers must balance the need to treat infections effectively while also considering the long-term implications of using a last-resort antibiotic. The medical community is increasingly aware of the importance of preserving the efficacy of existing antibiotics, including colistin, to ensure they remain viable options for future generations.Moreover, the global spread of colistin-resistant bacteria has alarmed public health officials. Studies have shown that colistin resistance can be transferred between different bacterial species, complicating infection control efforts. This highlights the need for ongoing surveillance and research to monitor the prevalence of colistin resistance and develop new strategies to combat resistant infections.In conclusion, colistin represents both a valuable tool and a significant challenge in the fight against antibiotic resistance. As we navigate the complexities of modern medicine, it is essential to understand the role of colistin in treating infections and the implications of its use. By doing so, we can better prepare for a future where antibiotic resistance continues to pose a threat to public health. The careful management of colistin and similar antibiotics will be critical in ensuring that they remain effective in the battle against resistant bacteria. In this context, colistin (多粘菌素) serves as a reminder of the delicate balance required in antibiotic prescribing practices and the ongoing need for innovation in the development of new antimicrobial agents.

多粘菌素（colistin）是一种多粘菌素类抗生素，近年来因其对多重耐药细菌的有效性而受到广泛关注。该药物最初在20世纪40年代被发现，但随着新抗生素的开发，多粘菌素逐渐被遗忘。然而，随着抗生素耐药性的上升，尤其是革兰氏阴性细菌的耐药性，多粘菌素作为最后的治疗选择重新回到了医学前沿。这一复兴引发了关于其使用、有效性及依赖这种古老药物在现代医学中可能产生的后果的讨论。多粘菌素的作用机制涉及破坏细菌细胞膜，导致细胞死亡。这对于像大肠杆菌和肺炎克雷伯菌这样的细菌尤其有效，这些细菌因对多种抗生素的耐药性而臭名昭著。尽管其效果显著，但多粘菌素的使用并非没有风险。它可能导致肾毒性，这意味着它可能损害肾脏，尤其是在高剂量或长期使用时。在临床环境中，多粘菌素通常被保留用于其他抗生素无效的严重感染。其使用通常由敏感性测试指导，以确保仅在绝对必要时给予。这种谨慎的方法至关重要，因为不加选择地使用多粘菌素可能导致进一步的耐药性，使其在未来的有效性降低。多粘菌素的重新引入治疗方案引发了关于抗生素管理的伦理问题。医疗提供者必须在有效治疗感染的需求与考虑使用最后手段抗生素的长期影响之间找到平衡。医学界越来越意识到保护现有抗生素有效性的重要性，包括多粘菌素，以确保它们在未来几代中仍然是可行的选择。此外，多粘菌素耐药细菌的全球传播也让公共卫生官员感到警惕。研究表明，多粘菌素耐药性可以在不同的细菌种类之间转移，复杂化了感染控制工作。这突显了持续监测和研究的必要性，以跟踪多粘菌素耐药性的流行，并制定新的策略来对抗耐药性感染。总之，多粘菌素在抗击抗生素耐药性方面既是宝贵的工具，也是重大挑战。当我们应对现代医学的复杂性时，理解多粘菌素在治疗感染中的作用及其使用的影响至关重要。通过这样做，我们可以更好地为未来做好准备，在这个抗生素耐药性继续威胁公共健康的时代。合理管理多粘菌素和类似抗生素将是确保它们在抵御耐药细菌战斗中保持有效性的关键。在这一背景下，多粘菌素（colistin）提醒我们在抗生素开处方实践中所需的微妙平衡，以及在新抗微生物剂开发中持续创新的必要性。